Manufacturer of Controlled Substances; Notice of Registration, 12635 [E7-4825]
Download as PDF
<![CDATA[
sroberts on PROD1PC70 with NOTICES
Federal Register / Vol. 72, No. 51 / Friday, March 16, 2007 / Notices
brings national attention to the problem
to increase public awareness of the need
for prevention and enhanced victim
services.
This meeting will primarily focus on
the Committee’s work and the federal
government’s response to violence
against women; there will, however, be
an opportunity for public comment on
the Committee’s role in providing
general policy guidance on
implementation of the Violence Against
Women Act of 1994, the Violence
Against Women Act of 2000, the
Violence Against Women Act of 2005
and related laws. April 3, 2007, from
8:30 a.m. until 5 p.m. and on April 4,
2007 from 8:30 a.m. until 12 noon, and
will include breaks and a working
lunch. Time will be reserved for public
comment on April 3 beginning at 9 a.m.
and ending at 9:30 a.m. See the section
below for information on reserving time
for public comment.
Access: This meeting will be open to
the public but registration on a spaceavailable basis is required. Persons who
wish to attend must register at least six
(6) days in advance of the meeting by
contacting Sandy Lonick by e-mail at:
Saundra.Lonick@usdoj.gov; or fax: (202)
307–3911. All attendees will be required
to sign in at the meeting registration
desk. Please bring photo identification
and allow extra time prior to the
meeting. The meeting site is accessible
to individuals with disabilities.
Individuals who require special
accommodations in order to attend the
meeting should notify Sandy Lonick by
e-mail at: Saundra.Lonick@usdoj.gov; or
fax at: (202) 307–3911, no later than
March 23, 2007. After this date, we will
attempt to satisfy accommodation
requests, but cannot guarantee the
availability of any requests.
Written Comments: Interested parties
are invited to submit written comments
by March 23, 2007 to Sandy Lonick at
The National Advisory Committee on
Violence Against Women, 800 K Street,
NW., Ste. 920, Washington, DC 20530.
Comments may also be submitted by email at Saundra.Lonick@usdoj.gov; or
fax at (202) 307–3911.
Public Comment: Persons interested
in participating during the public
comment period of the meeting, which
will discuss the implementation of the
Violence Against Women Act of 1994
and the Violence Against Women Act of
2000, the Violence Against Women Act
of 2005 and related legislation, are
requested to reserve time on the agenda
by contacting Sandy Lonick by e-mail at
Saundra.Lonick@usdoj.gov; or fax at
(202) 307–3911. Requests must include
the participant’s name, organization
represented, if appropriate, and a brief
VerDate Aug<31>2005
15:24 Mar 15, 2007
Jkt 211001
description of the issue. Each
participant will be permitted
approximately 3 to 5 minutes to present
comments, depending on the number of
individuals reserving time on the
agenda. Participants are also encouraged
to submit two written copies of their
comments at the meeting.
Given the expected number of
individuals interested in presenting
comments at the meeting, reservations
should be made as soon as possible.
Persons unable to obtain reservations to
speak during the meetings are
encouraged to submit written
comments, which will be accepted at
the meeting site or may be mailed to the
Committee at 800 K Street, NW., Ste.
920, Washington, DC 20530.
Mary Beth Buchanan,
Acting Director, Office on Violence Against
Women.
[FR Doc. E7–4820 Filed 3–15–07; 8:45 am]
BILLING CODE 4410–FX–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated July 26, 2006, and
published in the Federal Register on
August 2, 2006, (71 FR 43814–43815),
Siegfried (USA), Inc., Industrial Park
Road, Pennsville, New Jersey 08070,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the basic classes of
controlled substances listed in schedule
II:
Drug
Fmt 4703
Dated: March 9, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–4825 Filed 3–15–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Foreign Claims Settlement
Commission
[F.C.S.C. Meeting Notice No. 3–07]
Sunshine Act Meeting
II
II
II
II
II
II
II
II
II
II
II
II
The Foreign Claims Settlement
Commission, pursuant to its regulations
(45 CFR Part 504) and the Government
in the Sunshine Act (5 U.S.C. 552b),
hereby gives notice in regard to the
scheduling of meetings for the
transaction of Commission business and
other matters specified, as follows:
DATE AND TIME: Thursday, March 29,
2007, at 1 p.m.
SUBJECT MATTER: Issuance of Proposed
Decisions, Amended Proposed
Decisions, and Amended Final
Decisions in claims against Albania.
STATUS: Open.
All meetings are held at the Foreign
claims Settlement Commission, 600 E
Street, NW., Washington, DC. Requests
for information, or advance notices of
intention to observe an open meeting,
may be directed to: Administrative
Officer, Foreign Claims Settlement
II
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
Siegfried (USA) Inc.’s application for
renewal requested that DEA add
Hydromorphone (9150) to its
registration. DEA is reviewing this
request. DEA’s granting of Siegfried
(USA) Inc.’s application for renewal
Frm 00046
does not include the authority to handle
Hydromorphone (9150). When DEA has
completed its review of the firm’s
request to add Hydromorphone (9150)
to its registration, DEA will publish its
decision in the Federal Register.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Siegfried (USA), Inc. to manufacture the
listed basic classes of controlled
substances is consistent with the public
interest at this time. DEA has
investigated Siegfried (USA), Inc. to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Schedule
Amphetamine (1100) ....................
Methylphenidate (1724) ................
Amobarbital (2125) .......................
Pentobarbital (2270) .....................
Secobarbital (2315) ......................
Glutethimide (2550) ......................
Codeine (9050) .............................
Oxycodone (9143) ........................
Hydrocodone (9193) .....................
Methadone (9250) ........................
Methadone intermediate (9254) ...
Dextropropoxyphene, bulk (nondosage forms) (9273).
Morphine (9300) ...........................
PO 00000
12635
Sfmt 4703
E:\FR\FM\16MRN1.SGM
16MRN1
]]>Agencies
[Federal Register Volume 72, Number 51 (Friday, March 16, 2007)]
[Notices]
[Page 12635]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-4825]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Registration
By Notice dated July 26, 2006, and published in the Federal
Register on August 2, 2006, (71 FR 43814-43815), Siegfried (USA), Inc.,
Industrial Park Road, Pennsville, New Jersey 08070, made application by
renewal to the Drug Enforcement Administration (DEA) to be registered
as a bulk manufacturer of the basic classes of controlled substances
listed in schedule II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Amphetamine (1100)......................... II
Methylphenidate (1724)..................... II
Amobarbital (2125)......................... II
Pentobarbital (2270)....................... II
Secobarbital (2315)........................ II
Glutethimide (2550)........................ II
Codeine (9050)............................. II
Oxycodone (9143)........................... II
Hydrocodone (9193)......................... II
Methadone (9250)........................... II
Methadone intermediate (9254).............. II
Dextropropoxyphene, bulk (non-dosage forms) II
(9273).
Morphine (9300)............................ II
------------------------------------------------------------------------
The company plans to manufacture the listed controlled substances
in bulk for distribution to its customers.
Siegfried (USA) Inc.'s application for renewal requested that DEA
add Hydromorphone (9150) to its registration. DEA is reviewing this
request. DEA's granting of Siegfried (USA) Inc.'s application for
renewal does not include the authority to handle Hydromorphone (9150).
When DEA has completed its review of the firm's request to add
Hydromorphone (9150) to its registration, DEA will publish its decision
in the Federal Register.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and determined that the registration of
Siegfried (USA), Inc. to manufacture the listed basic classes of
controlled substances is consistent with the public interest at this
time. DEA has investigated Siegfried (USA), Inc. to ensure that the
company's registration is consistent with the public interest. The
investigation has included inspection and testing of the company's
physical security systems, verification of the company's compliance
with state and local laws, and a review of the company's background and
history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with
21 CFR 1301.33, the above named company is granted registration as a
bulk manufacturer of the basic classes of controlled substances listed.
Dated: March 9, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E7-4825 Filed 3-15-07; 8:45 am]
BILLING CODE 4410-09-P
